Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Ambrx Biopharma (AMAM).
The recent merger led to significant changes for a company, including the termination of its Employee Share Purchase Plan and the delisting of its shares from the Nasdaq Global Select Market. Following the merger’s completion, Johnson & Johnson acquired the company for an equity value of approximately $2 billion. Shareholders now only hold the right to receive the merger consideration, losing all previous stockholder rights. The merger also resulted in comprehensive corporate governance shifts, with all pre-merger directors resigning and being replaced by the directors of the acquiring subsidiary. Additionally, the company’s executive employment agreements were amended, with the outgoing CEO receiving a sizable severance package and accelerated payout of restricted cash awards.
For an in-depth examination of AMAM stock, go to TipRanks’ Stock Analysis page.